The current research on momelotinib
Description: Haifa Kathrin Al-Ali, MD from University of Leipzig, Leipzig, Germany discusses momelotinib at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark. Momelotinib is a JAK 1 and JAK 2 inhibitor and even though only data from the Phase I and Phase II trial is available, there has been positive results similar to ruxolitinib. Momelotinib has shown to have an essentially positive impact with patients with anemia and transfusion dependency. This differing result to ruxolitinib is thought to be due to momelotinib’s inhibition of the hepcidin production pathway in hepatocytes. However, momelotinib has a specific side-effect, peripheral neuropathy, which occurs in approximately every second patient.
Shared By : VJHemOnc
Posted on : 06/30/16
Added : 2 years ago